A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

Completed · Phase 2 · Has a placebo group

Conditions studied: Overweight and Obesity, Healthy

In brief

Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily \[BID\]) or placebo for 5 days beginning on Day 1. On Day 2, all participants will receive a single subcutaneous injection of a Glucagon-like Peptide-1 (GLP-1) agonist (semaglutide). Participants will remain at the clinical research unit for the duration of the treatment period. The goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a GLP-1 agonist, in the management of gastrointestinal side effects commonly associated with GLP-1 agonists for overweight or obesity. Adverse event information will be collected. Gastrointestinal (GI)-specific questionnaires will be used to capture additional details if GI-related adverse events are reported.

Key facts

Study ID

NCT06500429

Run by

Neurogastrx, Inc.

People needed

120

Starts

2024-06-24

Expected to finish

2024-09-13

Last updated by the study team

2025-09-04

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult
• Male or female
• BMI between 22 - 35 kg/m2 at screening

You may not qualify if…

• Presence or history of illness that might confound the results of the study or pose an -
• History of presence of gastroparesis, gallbladder disease, acute or chronic pancreatitis, or surgery of the abdomen
• History or presence of Type 1 or Type 2 diabetes

Where it is running

• Celerion — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.